Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients.
Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients. The parameters that will be measured will include clinical, lab, echo, and quality of life questionnaires.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
standard of care
Two IV doses
Department of internal medicine A
Tel Aviv, Israel
Functioning improvement
NYHA assesment (New York Heart Association (NYHA) Functional Classification)
Time frame: 5 days after second administration
Quality of life improvement
KCCQ questionnaires
Time frame: 5 days after second administration
Functioning improvement
NYHA assesment (New York Heart Association (NYHA) Functional Classification)
Time frame: 1 month after second administration
Quality of life improvement
KCCQ (The Kansas City Cardiomyopathy Questionnaire)
Time frame: 1 month after second administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.